Microvida, Laboratory of Medical Microbiology, Amphia Hospital, Breda, The Netherlands.
Microvida, Laboratory of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Antimicrob Resist Infect Control. 2024 Sep 12;13(1):102. doi: 10.1186/s13756-024-01460-y.
To determine the prevalence, trends, and potential nosocomial transmission events of the hidden reservoir of rectal carriage of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E).
From 2013 to 2022, yearly point prevalence surveys were conducted in a large Dutch teaching hospital. On the day of the survey, all admitted patients were screened for ESBL-E rectal carriage using peri-anal swabs and a consistent and sensitive selective culturing method. All Enterobacterales phenotypically suspected of ESBL production were analysed using whole genome sequencing for ESBL gene detection and clonal relatedness analysis.
On average, the ESBL-E prevalence was 4.6% (188/4,119 patients), ranging from 2.1 to 6.6% per year. The ESBL-prevalence decreased on average 5.5% per year. After time trend correction, the prevalence in 2016 and 2020 was lower compared to the other year. Among the ESBL-E, Escherichia coli (80%) and CTX-M genes (85%) predominated. Potential nosocomial transmission events could be found in 5.9% (11/188) of the ESBL-E carriers.
The ESBL-E rectal carriage prevalence among hospitalized patients was 4.6% with a downward trend from 2013 to 2022. The decrease in ESBL-E prevalence in 2020 could have been due to the COVID-19 pandemic and subsequent countrywide measures as no nosocomial transmission events were detected in 2020. However, the persistently low ESBL-E prevalences in 2021 and 2022 suggest that the decline in ESBL-E prevalence goes beyond the COVID-19 pandemic, indicating that overall ESBL-E carriage rates are declining over time. Continuous monitoring of ESBL-E prevalence and transmission rates can aid infection control policy to keep antibiotic resistance rates in hospitals low.
确定产超广谱β-内酰胺酶肠杆菌科(ESBL-E)直肠携带的隐性储库的流行率、趋势和潜在的医院内传播事件。
2013 年至 2022 年,在一家大型荷兰教学医院进行了年度点患病率调查。在调查当天,使用肛周拭子和一致且敏感的选择性培养方法筛查所有入院患者的 ESBL-E 直肠携带情况。使用全基因组测序对所有表型疑似产 ESBL 的肠杆菌科进行分析,以检测 ESBL 基因并进行克隆相关性分析。
平均而言,ESBL-E 的流行率为 4.6%(4119 名患者中的 188 名),每年为 2.1%至 6.6%。ESBL 流行率平均每年下降 5.5%。经过时间趋势校正后,2016 年和 2020 年的流行率低于其他年份。在 ESBL-E 中,大肠杆菌(80%)和 CTX-M 基因(85%)占主导地位。在 5.9%(11/188)的 ESBL-E 携带者中发现了潜在的医院内传播事件。
住院患者中 ESBL-E 的直肠携带率为 4.6%,2013 年至 2022 年呈下降趋势。2020 年 ESBL-E 流行率的下降可能是由于 COVID-19 大流行以及随后的全国范围内的措施所致,因为 2020 年未发现医院内传播事件。然而,2021 年和 2022 年持续较低的 ESBL-E 流行率表明 ESBL-E 流行率的下降超出了 COVID-19 大流行的范围,表明总体上 ESBL-E 携带率随着时间的推移呈下降趋势。持续监测 ESBL-E 的流行率和传播率有助于制定感染控制政策,以保持医院内抗生素耐药率较低。